Dilip Buildcon and STL Consortium Declared Lowest Bidder for BSNL Bharat Net Phase-III Project

Key Takeaways from BSNL Project:

• DBL-STL Consortium declared Lowest Bidder for BSNL Bharat Net Phase-III.
• The contract value is  Rs 1,625.36 crore, funded by USOF.
• DBL’s Share to execute 70.23% of the project.
• Middle-mile and last-mile connectivity for Jammu & Kashmir and Ladakh, with 3-year construction and 10-year maintenance.

The project, funded by the Universal Service Obligation Fund (USOF), aims to provide broadband connectivity in the Jammu & Kashmir and Ladakh regions. The total value of the contract is Rs 1,625.36 crore, including GST.

Under this contract, DBL’s portion of the project execution is 70.23%. The scope involves the development, upgradation, and operation of the middle-mile and last-mile network as part of the Bharat Net initiative, which will be executed over a three-year construction period, followed by a 10-year maintenance contract.

The BSNL Bharat Net Phase-III project is part of the government’s efforts to improve broadband connectivity in remote areas.

About Bharat Sanchar Nigam Limited:

Bharat Sanchar Nigam Limited (BSNL) was established on 15th September 2000 following the corporatisation of the Department of Telecom Services. A 100% government-owned entity, BSNL provides a comprehensive range of telecom services across India, excluding Delhi and Mumbai. These include wireline and wireless services, GSM mobile (2G, 3G, 4G), broadband (including FTTH), Wi-Fi, enterprise data solutions, and more. BSNL operates with a large customer base and a network that spans the length and breadth of the country. Its mission is to become India’s leading telecom provider, focusing on customer care, technological innovation, and expanding connectivity, including in rural areas.

About Dilip Buildcon Limited:

Dilip Buildcon Limited (DBL) is a leading Engineering, Procurement, and Construction (EPC) company based in India, specialising in infrastructure development. Founded in 1987, DBL has grown into one of India's largest road-focused EPC firms, with a fleet of over 10,340 machinery and 26,743 employees. The company is committed to excellence, innovation, and sustainable growth, contributing significantly to India's infrastructure landscape. With a focus on delivering high-quality projects and leveraging advanced technology such as drone and GPS monitoring, DBL is shaping India’s future through its engineering capabilities. Under the leadership of Chairman and Managing Director, Dilip Suryavanshi, DBL continues to excel in the sector.

About Sterlite Technologies Limited: 

Sterlite Technologies Limited (STL) is a leading global provider of optical and digital solutions, delivering advanced technologies to build 5G, rural, FTTx, enterprise, and data centre networks. Headquartered in India, STL operates across four continents with manufacturing facilities in 10 countries, serving customers in over 100 nations. The company focuses on innovation, research and development, and sustainability, aiming for Net Zero emissions by 2030. With a diverse portfolio, STL offers optical connectivity, digital solutions, and services, driving digital transformation globally. Its commitment to quality and customer-centricity has earned it numerous industry accolades, establishing STL as a trusted network solutions provider.

Key Takeaways from Adani Enterprises Joint Venture:

• Adani signed an agreement with Eurotunnel and Ospree to form a free zone company in the UAE.
• Ospree holds 51%, ETJV holds 49% in the JV.
• JV set up with AED 100,000 authorised capital.
• JV targets operations in France and other regions as part of Adani's global growth strategy.

The agreement aims to establish a new free zone company in the United Arab Emirates (UAE). This JV will primarily operate in France and other mutually agreed territories. 

The company will be set up with an authorised share capital of AED 100,000 (approximately Rs 22.5 million), divided into 10,000 shares with a nominal value of AED 10 each.

Under the agreement, Ospree will hold a 51% stake in the joint venture, while ETJV will own 49%. Both Ospree and ETJV will each appoint two directors to the board of the new company, and decisions will be made through unanimous voting.

This strategic collaboration is part of Adani Enterprises' continued expansion into international markets, further strengthening its position in global retail and business operations.

About Adani Enterprises Limited:

Adani Enterprises Limited (AEL) is a key part of the Adani Group, recognised as India's largest listed business incubator. The company operates across four core sectors: energy and utilities, transportation and logistics, consumer goods, and primary industries. AEL is committed to driving large-scale, impactful projects that support India's growth and infrastructure needs. With a balanced portfolio of established ventures and emerging enterprises, Adani Enterprises focuses on creating sustainable value for its stakeholders. The company's vision is to lead in businesses that enrich lives and contribute to nation-building through responsible, long-term value creation. 

Key Takeaways from Entero Healthcare: 

• Entero Healthcare Solutions Ltd. has entered into an MoU to acquire 100% of Shree Enterprises, a firm in pharmaceutical distribution.
• The acquisition, valued at Rs 231.12 million, will be completed by 31st January 2025 and will be financed via cash consideration.
• Shree Enterprises, with a turnover of Rs 443.78 million in FY 2023-2024, specialises in wholesale distribution of pharmaceuticals and allied products.
• The deal is a related-party transaction but will be conducted at arm's length, with no direct involvement of Entero's promoter group in Shree Enterprises.

The acquisition, valued at up to Rs 231.12 million, will be completed by 31st January 2025, and will be financed through cash consideration. The deal will allow Entero to strengthen its position in the pharmaceutical distribution business and generate additional revenue.

Shree Enterprises, a partnership firm based in Thiruvananthapuram, is engaged in the wholesale distribution of pharmaceuticals and allied products. In the financial year 2023-2024, the company recorded a turnover of Rs 443.78 million.

This acquisition is a related-party transaction, as directors of Entero’s subsidiary are partners in Shree Enterprises. However, the transaction will be conducted at arm’s length, and the promoter group of Entero has no direct interest in Shree Enterprises.

About Entero Healthcare Solutions Limited:

Entero Healthcare Solutions Limited, founded in 2018, is one of India's largest and fastest-growing healthcare product distribution platforms. With a pan-India presence, Entero operates in 540 districts across 39 cities, offering a wide range of solutions for retail pharmacies, hospitals, medical devices, and consumables. The company is recognised for its advanced data analytics, technology integration, and compliant infrastructure. Entero is among the top three distributors in India by revenue and boasts the largest network of hospital customers. With a focus on innovation and efficient supply chain solutions, Entero continues to drive growth and value across the healthcare ecosystem.

About Shree Enterprises Limited:

Shree Enterprises (India) Private Limited (SEIPL) was founded in 1979 by Damodar Parshad Todi in Ludhiana, Punjab. With over 30 years of experience, his sons, Suresh Kumar Todi and Ramesh Todi, now lead the family business. SEIPL is a leading manufacturer of high-quality hosiery knitted fabrics, offering a wide range of yarns including cotton, synthetic, rayon, and special fibres like Lycra and Tencel. The company produces various fabrics for both winter and summer seasons using advanced machinery. Committed to quality, SEIPL ensures rigorous checks at every stage of production to deliver the best products to its customers.

Key Takeaways from Alembic Pharma’s Nod for Ivabradine Tablets:

• Alembic Pharmaceuticals has received US FDA final approval for Ivabradine Tablets, 5 mg and 7.5 mg.
• The tablets are therapeutically equivalent to Amgen's Corlanor Tablets for treating chronic heart failure.
• Ivabradine Tablets have an estimated market size of $145.3 million for the 12 months ending September 2024.
• This approval marks Alembic's total US FDA ANDA approvals at 218, including 192 final and 26 tentative approvals.

The approved tablets are therapeutically equivalent to the reference drug, Corlanor Tablets, by Amgen Inc. Ivabradine is used to reduce the risk of hospitalisation in patients with chronic heart failure. 

The tablets are expected to have a market size of approximately $145.3 million for the year ending September 2024. This approval brings Alembic's total number of US FDA ANDA approvals to 218, including 192 final approvals and 26 tentative approvals.

About Alembic Pharmaceuticals Limited:

Alembic Pharmaceuticals Limited, headquartered in Vadodara, Gujarat, is one of India's leading pure-play pharmaceutical companies. Specialising in the manufacturing and marketing of India Formulations, International Generics, and Active Pharmaceutical Ingredients (APIs), Alembic has vertical integration capabilities across its operations. With over $600 million in revenue, a third of which comes from the Indian market, Alembic has a strong presence in the global pharmaceutical industry. The company was established in 1907 and, following a demerger in 2010, Alembic Pharmaceuticals became a separate entity focused on expanding its international footprint and advancing healthcare solutions worldwide.